Examination on the merits is awaited.

Respectfully submitted,

SMITH, GAMBRELL & RUSSELL, LLP

By: _____

Michael K. Carrier, Reg. No. 42,391
1850 M Street, N.W., Suite 800
Washington, D.C. 20036
Telephone: (202) 659-2811
Fax: (202) 263-4329

June 15, 2001

"Marked-Up" Copy of the Previous Claims

"Marked-Up" Copy of Previous Claims

10. Method according to [any of the previous claims] claim 1, wherein the toxin binding moiety is biotin, the spacers a, b, and c are 4, 7, 10-trioxa-1, 13-tridecanediamine and the trifunctional cross-linking moiety is 5-amino-1, 3-dicarboxybenzene.

11. Method according to [any of the claims 1-9] claim 1, wherein it is







17. Method according to [any of claims 13-16] claim 13, wherein the biotinylated targeting biomolecules are targeting molecules containing natural biotin or derivatives thereof,

the biotin-binding molecules are molecules containing avidin, streptavidin or derivatives thereof,

the biotinylated molecules are radiolabelled biotin derivatives containing a radiometal chelation moiety, and the effector molecule is a radionuclide or a cytoptoxic agent.

Amended Claims

Amended Claims

10. Method according to claim 1, wherein the toxin binding moiety is biotin, the spacers a, b, and c are 4, 7, 10-trioxa-1, 13-tridecanediamine and the trifunctional cross-linking moiety is 5-amino-1, 3-dicarboxybenzene.

11. Method according to claim 1, wherein it is







17. Method according to claim 13, wherein the biotinylated targeting biomolecules are targeting molecules containing natural biotin or derivatives thereof,

the biotin-binding molecules are molecules containing avidin, streptavidin or derivatives thereof,

the biotinylated molecules are radiolabelled biotin derivatives containing a radiometal chelation moiety, and the effector molecule is a radionuclide or a cytoptoxic agent.